Join us at #ESMO2026 for a rapid oral presentation on overall survival in the Phase 3 postMONARCH trial in HR+, HER2- advanced breast cancer following progression on prior CDK4/6i

Lilly Oncology Medical· @LillyOncMed · X·2026-10-23 22:00· 2 天前评分70

正文 · 原文

Join us at #ESMO2026 for a rapid oral presentation on overall survival in the Phase 3 postMONARCH trial in HR+, HER2- advanced breast cancer following progression on prior CDK4/6i + ET

1RO | Oct. 24, 10:59 -11:04 AM, Almeria Auditorium Hall 9

🔗https://e.lilly/4znE0mQ

#BreastCancer

195 浏览 · 2 赞 · 0 转发 · 0 回复

会议摘要

1RO按 Rapid oral 1: Breast cancer, advanced stage 对上

Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy

https://esmocongress.esmo.org

来源：Lilly Oncology Medical · x.com